;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Oasmia deal

    Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Business: Drug delivery Oasmia signed a research deal with an undisclosed pharma to use Oasmias XR-17 nanoparticle formulation technology. Oasmia will perform tests…

    Published on 7/21/2014
  • Pfizer, InnoPharma deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. InnoPharma Inc., Piscataway, N.J. Business: Drug delivery, Generics Pfizer will acquire sterile injectable company InnoPharma for $225 million in cash up front. InnoPharma is also …

    Published on 7/21/2014
  • Roche, Stratos Genomics deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Stratos Genomics Inc., Seattle, Wash. Business: Supply/Service Roche partnered with Stratos Genomics to develop unique chemistry applied to single molecule sequencing of …

    Published on 7/21/2014
  • Shire, AbbVie deal

    Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Pharmaceuticals AbbVie will acquire Shire for about L31.4 billion ($53.8 billion) in cash and stock. The offer comprises …

    Published on 7/21/2014
  • SimBioSys, Wiley deal

    SimBioSys Inc., Toronto, Ontario John Wiley & Sons Inc., Hoboken, N.J. Business: Supply/Service Wiley acquired scientific software tools company SimBioSys. SimBioSys uses computer-aided retrosynthetic analysis to …

    Published on 7/21/2014
  • Synthon, Abzena deal

    Synthon B.V., Nijmegen, the Netherlands Abzena Ltd. (LSE:ABZA), London, U.K. Business: Cancer, Antibodies Abzenas Antitope Ltd. subsidiary will use its EpiScreen ex vivo human T cell assay to determine the potential …

    Published on 7/21/2014
  • Tiziana Life Sciences, Italian Foundation for Cancer Research, European Institute of Oncology deal

    Tiziana Life Sciences plc (LSE:TILS), London, U.K. Italian Foundation for Cancer Research, Milan, Italy European Institute of Oncology, Milan, Italy Business: Diagnostic, Pharmacogenetics The Italian Foundation for …

    Published on 7/21/2014
  • Transgenomic, Integrated DNA deal

    Transgenomic Inc. (NASDAQ:TBIO), Omaha, Neb. Integrated DNA Technologies Inc., Coralville, Iowa Business: Functional genomics Transgenomic sold Integrated DNA Technologies (IDT) all of Transgenomics rights, title and …

    Published on 7/21/2014
  • Valeant Pharmaceuticals, PreCision Dermatology deal

    Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Montreal, Quebec PreCision Dermatology Inc., Cumberland, R.I. Business: Dermatology Valeant completed its acquisition of dermatology company PreCision for $…

    Published on 7/21/2014
  • Zalicus, Epirus deal

    Zalicus Inc., Cambridge, Mass. Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS), Boston, Mass. Business: Autoimmune, Biosimilars Epirus completed its reverse merger with Zalicus, and the combined company, named Epirus …

    Published on 7/21/2014
  • Abide Therapeutics, Celgene deal

    Abide Therapeutics Inc., Princeton, N.J. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Inflammation, Autoimmune Celgene paid Abide $50 million up front in exchange for an exclusive option to acquire Abide for …

    Published on 3/3/2014
  • Algeta, Bayer deal

    Algeta ASA (OSE:ALGETA), Oslo, Norway Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer Bayer completed its tender offer to acquire Algeta for NOK362 per share, or about NOK17.6 billion ($2.9 billion) in cash.…

    Published on 3/3/2014
  • Ardelyx, Sanofi deal

    Ardelyx Inc., Fremont, Calif. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Ardelyx granted Sanofi exclusive, worldwide rights to develop and commercialize Ardelyx's RDX002 program of …

    Published on 3/3/2014
  • Ariad, Merck deal

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Cancer Ariad disclosed in its 4Q13 and 2013 earnings that partner Merck is terminating an …

    Published on 3/3/2014
  • Basilea, Astellas deal

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Infectious Basilea will waive its rights to co-promote its isavuconazole (BAL8557) in the U.S. and Canada…

    Published on 3/3/2014
  • Cangene, Emergent BioSolutions deal

    Cangene Corp., Winnipeg, Manitoba Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Business: Infectious, Autoimmune Biodefense company Emergent completed the acquisition of Cangene for $3.24 per share in cash or $…

    Published on 3/3/2014
  • Caprion Proteomics, Global Genomics Group, Quintiles deal

    Caprion Proteomics Inc., Montreal, Quebec Global Genomics Group LLC, Richmond, Va. Quintiles Transnational Holdings Inc. (NYSE:Q), Research Triangle Park, N.C. Business: Genomics, Cardiovascular Quintiles' Expression …

    Published on 3/3/2014
  • Celladon, Servier deal

    Celladon Corp. (NASDAQ:CLDN), San Diego, Calif. Servier, Neuilly-sur-Seine, France Business: Endocrine/Metabolic Celladon granted Servier an exclusive option to license ex-U.S. rights to discover, develop and …

    Published on 3/3/2014
  • Centogene, LifeLabs deal

    Centogene Holding AG, Rostock, Germany LifeLabs Medical Laboratory Services, Toronto, Ontario Business: Diagnostic, Supply/Service LifeLabs acquired the Canadian business of genetic testing company Centogene. Under the …

    Published on 3/3/2014
  • Clal, Teva deal

    Clal Biotechnology Industries Ltd. (Tel Aviv:CBI), Tel Aviv, Israel Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Endocrine/Metabolic Clal's Andromeda Biotech Ltd. subsidiary will pay …

    Published on 3/3/2014
  • Critical Outcome Technologies, Portage Biotech deal

    Critical Outcome Technologies Inc. (TSX-V:COT), London, Ontario Portage Biotech Inc. (OTCBB:PTGEF; CNSX:PBT.U), Tortola, Virgin Islands Business: Cancer The companies signed a non-binding letter of intent to form a JV …

    Published on 3/3/2014
  • Discuva, Roche deal

    Discuva Ltd., Cambridge, U.K. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Infectious Roche and Discuva partnered to discover and develop antibiotics using the biotech's selective antibiotic target …

    Published on 3/3/2014
  • Egenix, TeraDiscoveries deal

    Egenix Inc., Millbrook, N.Y. TeraDiscoveries Inc., Research Triangle Park, N.C. Business: Cancer, Neurology TeraDiscoveries and Egenix partnered to discover and develop a cancer drug and an autism drug against the same …

    Published on 3/3/2014
  • Eli Lilly, Lohmann SE deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Lohmann SE, Cuxhaven, Germany Business: Veterinary Eli Lilly's Elanco animal health division will acquire poultry vaccine and feed additive company Lohmann. Elanco, which…

    Published on 3/3/2014
  • JCR Pharmaceuticals, Plasticell deal

    JCR Pharmaceuticals Co. Ltd. (Tokyo:4552), Ashiya, Japan Plasticell Ltd., London, U.K. Business: High throughput screening, Gene/Cell therapy Plasticell will work with JCR scientists to use Plasticell's CombiCult stem …

    Published on 3/3/2014

< Previous   1  2  3  4  5  6  7  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993